Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany
about
Ageing, musculoskeletal health and work[Treat to participation : Position paper of the German Society for Rheumatology on sustained improvement of functional health of patients with rheumatic and musculoskeletal diseases].[Trends of work force participation of patients with rheumatic diseases : results from German social insurance data and the national database of the German collaborative arthritis centers].Dense genotyping of immune-related susceptibility loci reveals new insights into the genetics of psoriatic arthritis.[Therapy of rheumatoid arthritis with methotrexate. Claims data analysis of treatment patterns].Health care costs associated with ankylosing spondylitis in Turkey: an analysis from nationwide real-world data.Standard medical care of patients with systemic lupus erythematosus (SLE) in large specialised centres: data from the Russian Federation, Ukraine and Republic of Kazakhstan (ESSENCE).Costs and outcomes for patients with rheumatoid arthritis treated with biological drugs in Sweden: a model based on registry data.Persistence with golimumab in immune-mediated rheumatic diseases: a systematic review of real-world evidence in rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritisEconomic burden of comorbidities in psoriasis patients in the United States: results from a retrospective U.S. database.Validity, reliability, and sensitivity-to-change properties of the psoriatic arthritis screening and evaluation questionnaire.Health care costs and costs associated with changes in work productivity among persons with systemic lupus erythematosus.Reduction in sickness absence in patients with rheumatoid arthritis receiving adalimumab: data from a German noninterventional study.Assessment of activity limitations with the health assessment questionnaire predicts the need for support measures in patients with rheumatoid arthritis: a multicenter observational study.Challenges comparing functional limitations in rheumatoid arthritis and ankylosing spondylitisTwo-year direct and indirect costs for patients with inflammatory rheumatic joint diseases: data from real-life follow-up of patients in the NOR-DMARD registry.The burden of psoriatic arthritis: a literature review from a global health systems perspective.Discriminant validity, responsiveness and reliability of the arthritis-specific Work Productivity Survey assessing workplace and household productivity in patients with psoriatic arthritisImpact of morning stiffness on working behaviour and performance in people with rheumatoid arthritis.Psoriasis beyond the skin: an expert group consensus on the management of psoriatic arthritis and common co-morbidities in patients with moderate-to-severe psoriasisQualifying unmet needs and improving standards of care in psoriatic arthritis.Improvements in productivity at paid work and within the household, and increased participation in daily activities after 24 weeks of certolizumab pegol treatment of patients with psoriatic arthritis: results of a phase 3 double-blind randomised plaThe significance of presenteeism for the value of lost production: the case of rheumatoid arthritis.Evolution of cost structures in rheumatoid arthritis over the past decade.Cost of illness for patients with arthritis receiving multidisciplinary rehabilitation careThe Cost of Ankylosing Spondylitis in the UK Using Linked Routine and Patient-Reported Survey Data.Biologic TNF inhibiting agents for treatment of rheumatoid arthritis: persistence and dosing patterns in Germany.Comparison of the Belgian Rheumatoid Arthritis Disability Assessment and Health Assessment Questionnaires as Tools to Predict the Need for Support Measures in Patients with Rheumatoid Arthritis.Socioeconomic and employment status of patients with rheumatoid arthritis in Korea.Economic impact of juvenile idiopathic arthritis and familial Mediterranean feverSick leave and work disability in patients with early arthritisThoughts on health economics in rheumatoid arthritisImproving patient flow of people with rheumatoid arthritis has the potential to simultaneously improve health outcomes and reduce direct costs.Health economic issues in rheumatoid arthritis.Medication adherence in patients in treatment for rheumatoid arthritis and systemic lupus erythematosus in a university hospital in BrazilThe psoriatic arthritis cost evaluation study: a cost-of-illness study on tumour necrosis factor inhibitors in psoriatic arthritis patients with inadequate response to conventional therapy.Systemic lupus erythematosus and the economic perspective: a systematic literature review and points to considerDisease activity, quality of life and indirect costs of psoriatic arthritis in Poland.The substantial burden of systemic lupus erythematosus on the productivity and careers of patients: a European patient-driven online surveyA discrete choice experiment to explore patients' willingness to risk disease relapse from treatment withdrawal in psoriatic arthritis.
P2860
Q26776450-CB0E6D09-A85C-4932-A3D9-8E385206A0ECQ30316308-B96260F7-4920-47A6-8E67-7A609FC80284Q30317576-BB10C5F9-14DF-460B-AF16-0D5A9D95F822Q30407889-DE9C88D1-72A4-41E4-A0D1-9CB89D1CCF4CQ30572825-34EE3647-69AA-42AD-92A6-815D3AD65351Q30603471-5E00F0C4-3E0C-48FA-8231-C99F3E0A07B2Q30900345-71384558-39F3-48BB-AB32-8B2BE298DE9DQ33516150-0F88A5EF-0BFA-40DF-B2BC-189A9F89253AQ33563272-456A2475-604F-477A-86F6-F8D1D0CC17D1Q33651728-2A926C84-0D68-4C8B-A92F-9B7DD414504AQ33750434-3D7FC95D-B994-4C35-9FE5-99F8FB807A05Q33871768-363DE626-EC36-4C67-B269-1987BC8B8A37Q34114195-2CA6870B-AC54-4E70-860E-937C494FC818Q34133993-141B2C29-90AD-4775-A1C2-14ACE1C0E1C7Q34192955-3FEF44E2-0F6E-4DE9-B9DF-21C4588935BFQ34249182-4937CA58-5304-449B-AE67-42D382066EE5Q34432846-D31F4E77-F08B-4826-A9FD-A09A190E938DQ34485175-4F5CC717-B0BE-466D-96B3-AF2027E34296Q34545029-22AE3120-C07A-4718-A04D-C41EC1169D56Q34643790-818DB174-9D86-49DE-B8FC-CEECF257C8BBQ34803582-A791D4E2-0E77-4570-A106-96CD53ACF9F6Q34818891-CE15B216-8B43-492C-8CFF-A1BDD4D70769Q35205360-D76C2635-CCD1-4D12-983B-17DF9485CF47Q35352526-E4D3DE75-B276-43E6-B8A3-AA9DD3FF3630Q35368403-360D70BA-53DD-48B1-B919-38558D57BA6BQ35694344-42C64312-A48F-4DB0-B4E1-82569380CC7FQ35851000-59E265E8-6D25-4504-BFCC-B3BC0AFBB19DQ35901757-89A6A29C-66B5-401D-839C-B5AE8629555EQ35954686-93564890-965F-4E1D-9741-864F71C737BBQ36056815-3159919B-E02A-4718-AD11-5109B1E54A34Q36166120-A6533959-EE66-415F-A6E6-75F008742289Q36171777-7C32F740-9B90-4581-8F4A-0FD3A6916AE4Q36243390-12E7593F-4957-4BE0-B9A6-E1777ABD879BQ36753625-903F0934-3C5E-4374-94E8-7CCB22DF7738Q36931621-4E0D8C18-59C2-482B-AB3C-F047C9DF9B8AQ36940942-91B27066-ECC5-40FA-9F88-4F839EF870D5Q37021770-5B31B270-567B-4920-8821-6B89BF07FC47Q37171900-B94A313B-6975-4112-A68F-D6658BCD8F76Q37309687-6246FB3B-3F89-4948-940C-10D0618DBFCCQ37427411-D6435093-9D7C-47E2-99E4-547E54FE214B
P2860
Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Cost of illness in rheumatoid ...... lupus erythematosus in Germany
@ast
Cost of illness in rheumatoid ...... lupus erythematosus in Germany
@en
type
label
Cost of illness in rheumatoid ...... lupus erythematosus in Germany
@ast
Cost of illness in rheumatoid ...... lupus erythematosus in Germany
@en
prefLabel
Cost of illness in rheumatoid ...... lupus erythematosus in Germany
@ast
Cost of illness in rheumatoid ...... lupus erythematosus in Germany
@en
P2093
P2860
P356
P1476
Cost of illness in rheumatoid ...... lupus erythematosus in Germany
@en
P2093
German Collaborative Arthritis Centres
M Schneider
S Merkesdal
P2860
P304
P356
10.1136/ARD.2005.046367
P407
P577
2006-03-15T00:00:00Z